Patterns of biologic and targeted-synthetic disease-modifying antirheumatic drug use in rheumatoid arthritis in Australia.

Ashley FletcherMarissa LassereLyn MarchCatherine HillClaire BarrettGraeme CarrollRachelle Buchbinder

Published in: Rheumatology (Oxford, England) (2022)

Switching between b/tsDMARDs was common among ARAD participants with RA, most commonly due to inefficacy or adverse effects. Durability of exposure and reasons for switching varied between b/tsDMARDs.

Keyphrases

rheumatoid arthritis
disease activity
interstitial lung disease
ankylosing spondylitis
cancer therapy
systemic sclerosis
systemic lupus erythematosus